

TRIOMED ENROLLS FIRST PATIENT IN A CLINICAL STUDY FOR SAFETY AND EFFICACY OF THE WEARABLE DEVICE - CARRY LIFE® CARDIO

Lund, May 20 – Triomed AB announces the start of the Clinical Study of the Safety and Efficacy of the Wearable Device - Carry Life Cardio. Carry Life Cardio delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients with Congestive Heart Failure

The trial is designed to study more about the increased ultrafiltration efficacy for Congestive Heart Failure patients with fluid overload. Ultrafiltration volume, dialysate glucose concentrations as well the patient's acceptability and tolerance of the wearable device will be evaluated. The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.

'Carry Life® -THE REVOLUTIONARY WEARABLE THERAPY SYSTEM - is the result of ten years of research and development, supported by world renowned medical expertise and specialist engineers. We are now taking the next step, creating a new way of living by enabling freedom of mobility, says Anders Wallenås, CEO'.

About Triomed

Triomed is a Swedish medical engineering company developing wearable dialysis system for Cardiac and Renal patients. Triomed was founded in 2005 and has today 15 employees and the head quarter is located in Lund, Sweden.

Triomed AB
Media Relations
Anders Wallenås
Anders.wallenas@triomed.se